Category: 3. Business

  • SBP injects Rs4.25tr via OMOs

    SBP injects Rs4.25tr via OMOs

    State Bank of Pakistan. Photo: File


    KARACHI:

    The State Bank of Pakistan (SBP) on Friday injected a total of Rs4.245 trillion into the financial system through reverse repo and Shariah-compliant Mudarabah-based open market operations (OMOs).

    According to the central bank, the liquidity injection included Rs3.914 trillion through conventional reverse repo OMOs and Rs331 billion via Islamic Mudarabah-based operations. The OMO was conducted for seven-day and 14-day tenors.

    For the seven-day reverse repo, the SBP received 18 bids totalling Rs3,643 billion at rates ranging between 11% and 11.07%, out of which 17 bids worth Rs3,642.5 billion were accepted at a rate of 11.01%. In the 14-day tenor, the central bank received 11 bids amounting to Rs272.5 billion, with accepted bids of Rs272 billion at a rate of 11.02%.

    In its Shariah-compliant Mudarabah-based OMO, the SBP received four bids for the seven-day tenor, offering Rs331 billion at returns from 11.06% to 11.12%. The entire amount was accepted at 11.06%, while no bids were received for the 14-day Islamic tenor.

    According to data released by the SBP, the rupee closed at Rs281.02 per dollar, gaining Rs0.01 from the previous day’s rate.

    Meanwhile, gold prices in Pakistan continued their downward trajectory, mirroring trends in the international market, where the precious metal struggled to recover despite slightly softer-than-expected US inflation data that bolstered expectations of a Federal Reserve rate cut next week.

    According to the rates issued by the All-Pakistan Gems and Jewellers Sarafa Association, the price of gold per tola fell by Rs2,000, settling at Rs431,862, while the price of 10 grams declined by Rs1,714 to Rs370,252.

    The fall marks the first weekly loss in nearly 10 weeks as global investors adjusted their positions ahead of next week’s US monetary policy announcement.

    On Thursday, the yellow metal had already recorded a sharp drop of Rs3,500 per tola, bringing local prices down from recent highs. The consistent downward pressure reflects international market sentiment, where gold has been trading in a narrow band after heavy profit-taking earlier in the week.

    Continue Reading

  • Strong economies keep airlines airborne

    Strong economies keep airlines airborne

    Emirates marks 40 years since first flight to Karachi as PIA awaits privatisation


    KARACHI:

    Forty years after Emirates’ maiden flight from Dubai to Karachi – operated with a Pakistan International Airlines (PIA) aircraft on lease and Pakistani crew, including captains – the two airlines stand worlds apart.

    Emirates, which relied on PIA’s support in 1985, is now a $37 billion global aviation powerhouse with nearly 400 aircraft. PIA, once a regional trailblazer that helped launch airlines like Emirates and Singapore Airlines, is drowning in debt exceeding Rs800 billion and edging towards privatisation.

    At Jinnah International Airport, Emirates marked its 40th anniversary with a ceremony attended by UAE Consul General Bakheet Ateeq Al-Rumaithi and aviation officials. A retrofitted Boeing 777 featuring Premium Economy cabins was showcased – a symbolic reminder of the airline’s transformation from modest beginnings into one of the world’s leading carriers.

    Meanwhile, PIA is struggling to stay airborne. The government has created PIA Holding Company to absorb Rs660 billion in legacy debt, leaving about Rs300 billion in operational liabilities to the Civil Aviation Authority (CAA).

    The privatisation drive, part of IMF-mandated reforms, has attracted five consortia, including groups led by Lucky Cement, Arif Habib Group, Fauji Fertiliser, and two domestic airlines – Airblue and Serene Air. However, aviation analysts warn that any new buyer will face “turbulent skies” in an industry globally known for wafer-thin margins.

    Pakistan’s aviation sector remains vastly underdeveloped compared with regional peers. According to the benchmarking data, only 6 million domestic passengers flew in Pakistan last year – a mere 2.4% of the population.

    In contrast, Indonesia, with a slightly higher population and per-capita GDP of $4,860, recorded 57 million domestic passengers (19.9%). India moved 154 million passengers domestically (11%), while China’s figure exceeded 665 million (47.5%). The US leads with 876 million domestic travellers – almost 2.5 times its population – highlighting how aviation demand correlates strongly with income, tourism, and infrastructure.

    Pakistan’s per-capita GDP of $1,581 underscores this disparity. “An airline grows or shrinks with its economy,” says aviation consultant Afsar Malik, who has over three decades of industry experience. “When GDP rises, air travel doubles that growth rate; when GDP falls, losses multiply. Pakistan’s stagnating economy and weak tourism have clipped PIA’s wings.”

    Despite the grim numbers, investor interest in the skies is rising. New private carriers such as Air Karachi and Air Punjab are preparing to launch, while South Air and Saudi Arabia’s Riyadh Air are reportedly eyeing Pakistani routes.

    “Aviation carries a charisma that attracts businessmen – it’s about name and fame and less about fortune,” says Malik. “But most underestimate the risks.” Globally, only about 20% of airlines make profits, 30% break even, and half incur losses.

    Malik points out that airline ventures demand massive financial stamina. If an investor puts in Rs1 billion and borrows Rs3 billion, a single year of loss can wipe out his equity. “And once you are in, it’s hard to exit.” The story of Shaheen Air, which collapsed under Rs5 billion debt, is a cautionary tale.

    The government’s latest plan drops earlier conditions that reserved a 40% state stake and required $300 million in new investment, making the offer more flexible. Still, potential buyers must contend with inherited liabilities, outdated systems, and intense competition from foreign and domestic airlines.

    Economic experts argue that the state should exit commercial aviation altogether. “Airline business is capital-intensive and politically volatile,” says one former PIA finance director. “Government control has cost taxpayers billions; private ownership may be the only way forward.”

    Industry insiders say Emirates’ success lies in disciplined management, global recruitment, and strategic geography. Based in Dubai – a hub between Europe and Asia – Emirates capitalised on transit traffic and luxury branding. Its leadership, including long-time president Sir Tim Clark, maintained operational independence and long-term planning, backed by state ownership but run on commercial principles.

    As Emirates celebrates four decades of connecting Pakistan to the world, its story stands as both an inspiration and a reminder – that success in the skies demands not just wings, but vision, discipline, and an economy strong enough to sustain flight.

    Continue Reading

  • Immune Checkpoint Add-Ons to BCG: No Slam Dunk – Medscape

    1. Immune Checkpoint Add-Ons to BCG: No Slam Dunk  Medscape
    2. ESMO: Results for AZ’s Imfinzi in early bladder cancer type suggest it measures up to Pfizer candidate  Fierce Pharma
    3. ESMO 2025 | POTOMAC supports add-on durvalumab for high-risk NMIBC  springermedicine.com
    4. Adding atezolizumab to BCG does not improve EFS in BCG-naïve NMIBC  Urology Times
    5. Andrea Necchi: The Results of POTOMAC trial are out in The Lancet  Oncodaily

    Continue Reading

  • FDA Issues Emergency Use Authorization for New World Screwworm Drug for Dogs – fda.gov

    1. FDA Issues Emergency Use Authorization for New World Screwworm Drug for Dogs  fda.gov
    2. Elanco’s Credelio™ (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs  PR Newswire
    3. Elanco gets FDA emergency authorization for screwworm treatment in dogs  StreetInsider
    4. Elanco (NYSE: ELAN) receives first FDA EUA; Credelio showed 100% efficacy in 24 hours  Stock Titan

    Continue Reading

  • The Trade Desk stock falls after Amazon offers free DSP testing

    The Trade Desk stock falls after Amazon offers free DSP testing

    Investing.com — The Trade Desk Inc. (NASDAQ: TTD) stock fell 3% Friday afternoon following an Adweek report that Amazon is offering agencies free head-to-head testing of its demand-side platform (DSP) against competitors.

    According to the report, which cited a pitch deck and sources familiar with the matter, Amazon is approaching agencies with an offer to fund comparative tests between its DSP and rival platforms, including covering costs for competitors’ ad inventory, technology, and media measurement tools. The proposed tests would run dual campaigns for 4-6 weeks with equal budgets allocated to both Amazon’s DSP and the competing platform.

    In the leaked presentation slides, Amazon described the testing program as “designed to empirically demonstrate the performance of Amazon DSP versus other DSPs” and an “opportunity to evaluate and optimize your programmatic advertising strategy through a controlled test with comprehensive analysis.”

    The Trade Desk, which operates one of the leading independent demand-side platforms in the digital advertising ecosystem, appears to be facing increased competitive pressure from Amazon’s aggressive expansion in the advertising technology space.

    Related articles

    The Trade Desk stock falls after Amazon offers free DSP testing

    17 Undervalued Small-Cap Tech Stocks Primed to Outperform in Q4

    Gold: Will Safe-Haven Demand Push Yellow Metal Even Higher?

    Continue Reading

  • Grindr Gets Buyout Offer Valuing Company at Nearly $3.5 Billion – The Wall Street Journal

    1. Grindr Gets Buyout Offer Valuing Company at Nearly $3.5 Billion  The Wall Street Journal
    2. Grindr discloses buyout proposal at $18 per share  Sherwood News
    3. Grindr shares pop on buyout offer from controlling shareholders  Proactive financial news
    4. Grindr Stock Soars Amid Buyout Buzz  TipRanks
    5. Grindr (NYSE:GRND) Downgraded to “Hold” Rating by Wall Street Zen  MarketBeat

    Continue Reading

  • Crude futures settle lower

    NEW YORK, Oct. 24 (Xinhua) — Oil prices declined on Friday.

    The West Texas Intermediate for December delivery dropped 28 cents, or 0.47 percent, to settle at 61.50 U.S. dollars a barrel on the New York Mercantile Exchange. Brent crude for December delivery lost 5 cents, or 0.08 percent, to settle at 65.94 dollars a barrel on the London ICE Futures Exchange. Enditem

    Continue Reading

  • Ontario’s $100 Billion Pension Dismisses Entire Asia Buyout Team

    Ontario’s $100 Billion Pension Dismisses Entire Asia Buyout Team

    Ontario Municipal Employees Retirement System is cutting its Asia buyout team, marking the latest change in the pension fund’s private equity unit as it reassesses its strategy.

    The Singapore-based private equity team for the region has a handful of members, according to people with knowledge of the matter who asked not to be identified because the details are confidential. The decision will be effective Dec. 31.

    Continue Reading

  • Revumenib Granted FDA Approval for R/R NPM1-Mutated AML

    The FDA has approved revumenib (Revuforj; Syndax Pharmaceuticals) for patients 1 year and older with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 (NPM1) mutation if there are no other satisfactory treatment options.1

    The approval was based on data from the phase 2 AUGMENT-101 (NCT04065399) trial, which found the rate of complete remission (CR) plus CR with partial hematological recovery (CRh) was 23.4% (95% CI, 13.8%-35.7%; P = .0014), according to the data published in May in Blood.2 Updated data presented at the 2025 annual meeting of the European Hematology Association (EHA) in June showed a CR/CRh rate of 25%.3

    According to the updated results presented at EHA, the median time to first CR/CRh was 2.8 months with a median duration of 4.7 months. The overall response rate was 48.1%.

    “The expanded FDA approval of Revuforj marks a major advancement in the management of acute leukemia patients,” Joshua F. Zeidner, MD, chief, Leukemia Research at the University of North Carolina, Lineberger Comprehensive Cancer Center, said in a statement.4 “For the first time, a targeted, oral therapy that is well tolerated and efficacious is approved for R/R NPM1-mutated AML and R/R KMT2A-translocated acute leukemia. The compelling clinical activity observed with Revuforj in clinical trials and clinical practice paves the way for a new standard of care for these 2 aggressive and difficult-to-treat blood cancers.”

    Examining Revumenib: Highlighting Efficacy and Adverse Events

    The data published in Blood also showed that responses were observed across various subgroups, regardless of previous hematopoietic stem cell transplantation (HSCT) and number of lines of therapy.2 CR/CRh rates were also similar among adults younger than 65 years or 65 years and older. Patients with previous venetoclax exposure had a CR/CRh rate of 16.7% (95% CI, 7.5%-30.2%), while patients without previous exposure had a CR/CRh rate of 43.8% (95% CI, 19.8%-70.1%).

    There were 5 adult patients who achieved an overall response and underwent allogeneic HSCT while in remission, with 3 of them subsequently resuming revumenib after transplant.

    In addition, 98.8% of patients experienced treatment-emergency adverse events (AEs), with 78.6% experiencing at least 1 treatment-related AE (TRAE) and 59.5% experiencing a grade 3 or higher TRAE.

    Additional safety findings were:

    • 76.2% of patients required a dose modification
    • 66.7% of patients required a dose interruption
    • 11.9% of patients requiring a dose reduction due to TRAEs
    • The most common TRAEs were QTcF prolongation (42.9%), vomiting (36.9%), febrile neutropenia (34.5%), hypokalemia (32.1%), nausea (28.6%), anemia (27.4%), diarrhea (27.4%), fatigue (23.8%), pyrexia (23.8%), epistaxis (21.4%), and peripheral edema (21.4%)

    “New treatment options are vitally needed for patients with NPM1-mutated AML whose disease has returned or not improved after previous treatment,” said Lore Gruenbaum, PhD, chief scientific officer of Blood Cancer United (formerly The Leukemia & Lymphoma Society). “The FDA approval of a precision treatment that selectively targets the pathway driving this form of AML offers new hope to patients and their loved ones.”

    Revumenib was previously approved in 2024 to treat R/R acute leukemia with a KMT2A translocation for patients 1 year and older.5

    References

    1. FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation. News release. FDA. October 24, 2025. Accessed October 24, 2025. https://www.cancernetwork.com/view/fda-approves-revumenib-in-r-r-npm1-mutant-aml

    2. Arellano ML, Thirman MJ, DiPersio JF, et al. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood. Published online May 7, 2025. Accessed May 8, 2025. doi:10.1182/blood.2025028357

    3. Joszt L. Revumenib shows efficacy in patients with AML and genetic alterations. AJMC®. June 12, 2025. Accessed October 24, 2025. https://www.ajmc.com/view/revumenib-shows-efficacy-in-patients-with-aml-and-genetic-alterations

    4. Syndax announces FDA approval of Revuforj (revumenib) in adult and pediatric patients with relapsed or refractory NPM1 mutated acute myeloid leukemia. News release. Syndax Pharmaceuticals. October 24, 2025. Accessed October 24, 2025. https://ir.syndax.com/news-releases/news-release-details/syndax-announces-fda-approval-revuforjr-revumenib-adult-and

    5. Rosa K. FDA approves revumenib for R/R acute leukemia with a KMT2A translocation. OncLive®. November 15, 2204. Accessed October 24, 2025. https://www.onclive.com/view/fda-approves-revumenib-for-r-r-acute-leukemia-with-a-kmt2a-translocation

    Continue Reading

  • Nvidia is backing a former Tesla executive’s bid to drive low-cost energy

    Nvidia is backing a former Tesla executive’s bid to drive low-cost energy

    By William Gavin

    Redwood Materials plans to meet the AI-fueled demand for energy with recycled electric-car batteries

    J.B. Straubel is a former Tesla executive who left to focus on his energy startup, Redwood Materials.

    A previous version of this report incorrectly listed Redwood’s valuation as of a 2023 funding round.

    The battery-recycling company founded by an ex-Tesla Inc. executive can count a high-profile artificial-intelligence company among investors in its latest funding round.

    Redwood Materials said Thursday it had raised $350 million in a round led by the venture-capital firm Eclipse and Nvidia Corp.’s (NVDA) venture-capital arm, NVentures. Nvidia’s contribution to the round was not disclosed, and a representative did not immediately return a request for comment.

    The fundraise comes as major AI players are scrambling to meet their power needs and as the U.S. is facing difficulties building out domestic mineral-supply chains. Currently, China is – by far – the dominant force in the global supply chains for cobalt, nickel and other minerals. And rising tensions between China and the U.S. have stoked worries that some companies, including carmakers, may get cut off from lithium-ion batteries and battery materials.

    Don’t miss: Quantum stocks are rising. Why they may be the Trump White House’s next investment.

    “This is a pivotal time for both Redwood and the United States, as curtailment in international supplies overlaps with intense domestic demand growth for these same materials and energy products,” the company said in a statement.

    Redwood said it would use the new cash to expand its growing energy-storage business, which it launched in June under the name Redwood Energy and which seeks to meet the quickly escalating demand for energy needed for AI data centers. By 2030, global power demand from data centers is set to grow 165% compared with 2023, according to Goldman Sachs.

    “AI is several things. AI is energy, AI is chips, the models and the application,” Nvidia CEO Jensen Huang said in a recent interview with CNBC’s “Squawk Box.” “And we need more energy.”

    Redwood believes it already has the supply chains necessary to match its ambitions. The company has said it receives batteries equivalent to 250,000 electric vehicles annually, or about 90% of all lithium-ion batteries and battery materials recycled in North America.

    Redwood’s core business involves recycling scrap from consumer electronics and batteries, extracting minerals like cobalt and nickel and selling those components back to partners and battery suppliers, including Toyota Motor Corp (JP:7203).

    Now it says it won’t take battery packs apart immediately, instead diverting what power remains to fuel low-cost, large-scale energy-storage systems. Once that energy is fully drained, the batteries are sent to be scrapped for parts as usual.

    “Low-cost, large-scale battery energy storage has emerged as the most immediate and scalable solution to enable AI factory deployment and unlock stranded grid and generation capacity,” Redwood said in a statement.

    Redwood was founded in 2017 by J.B. Straubel, a Tesla (TSLA) co-founder and executive who left the company to scale his startup. Straubel’s former employer is also seeking to meet growing energy demand.

    See more: This underrated Tesla business deserves more attention – and it’s not AI

    Beyond expanding its energy business, Redwood said it will also use the new capital to expand its refining and material-production capacity and build out its engineering and operations teams. The company was valued at $5 billion in late 2023, following its previous fundraising round, according to TechCrunch.

    The company is currently valued at about $6 billion, according to a source familiar with the matter.

    -William Gavin

    This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

    (END) Dow Jones Newswires

    10-24-25 1518ET

    Copyright (c) 2025 Dow Jones & Company, Inc.

    Continue Reading